Xderm0.05%

Clobetasol Propionate is a super-high-potency topical corticosteroid indicated for adults, the elderly, and children over 1 year of age to relieve the inflammatory and pruritic manifestations of steroid-responsive skin conditions that have not responded adequately to less potent corticosteroids.

It is commonly prescribed for the following dermatoses:

• Psoriasis (excluding widespread plaque psoriasis)
• Recalcitrant dermatoses that resist standard therapy
• Lichen planus
• Discoid lupus erythematosus
• Other resistant skin conditions that do not respond satisfactorily to less potent topical steroids

Because of its high potency, Clobetasol Propionate is generally reserved for short-term treatment of severe or stubborn lesions under medical supervision.

Clobetasol Propionate is available in multiple topical dosage forms, each standardised to a strength of 0.05% w/w (0.5 mg per gram):

• Cream: Each gram contains Clobetasol Propionate BP 0.5 mg (0.05% w/w).
• Ointment: Each gram contains Clobetasol Propionate BP 0.5 mg (0.05% w/w).
• Scalp Application: Each gram lotion contains Clobetasol Propionate BP 0.5 mg (0.05% w/w).
• Shampoo: Each gram shampoo contains Clobetasol Propionate BP 0.5 mg (0.05% w/w).
• Lotion: Each gram lotion contains Clobetasol Propionate BP 0.5 mg (0.05% w/w).
• Spray: Each gram spray contains Clobetasol Propionate BP 0.5 mg (0.05% w/w).

Other Topical corticosteroids

Clobetasol Propionate is a very potent (super-high-potency) topical corticosteroid with anti-inflammatory, antipruritic (anti-itch), and vasoconstrictive properties. It works through several complementary mechanisms to suppress inflammatory and late-phase allergic reactions in the skin.

At the cellular level, Clobetasol Propionate reduces the density of mast cells, inhibits the chemotaxis and activation of eosinophils, decreases the production of pro-inflammatory cytokines, and interferes with the metabolism of arachidonic acid.

Like other topical corticosteroids, its precise anti-inflammatory mechanism is not fully understood. However, corticosteroids are believed to act by inducing phospholipase A2 inhibitory proteins collectively known as lipocortins. These proteins are thought to regulate the biosynthesis of powerful inflammatory mediators such as prostaglandins and leukotrienes by blocking the release of their shared precursor, arachidonic acid, which is liberated from membrane phospholipids by the enzyme phospholipase A2.

Clobetasol Propionate is for external (cutaneous) use only. The choice of formulation should match the nature of the lesion:

• Creams are especially suitable for moist or weeping skin surfaces.
• Ointments are especially suitable for dry, lichenified, or scaly lesions.

Co-administered medicines that inhibit the liver enzyme CYP3A4—such as ritonavir and itraconazole—can slow the breakdown of corticosteroids. This may increase systemic exposure to Clobetasol Propionate and raise the risk of corticosteroid-related side effects, particularly with prolonged use or application to large areas.

The most commonly reported local reactions are a burning and stinging sensation at the application site. Less frequent effects include itching, skin atrophy (thinning), and cracking or fissuring of the skin.

Prolonged use of large amounts, or treatment of extensive areas, can lead to enough systemic absorption to cause features of hypercorticism (Cushing-like effects). Intensive treatment with this highly potent corticosteroid may also cause local atrophic changes such as skin thinning, striae (stretch marks), and dilatation of superficial blood vessels—especially under occlusive dressings or in skin folds.

Other reported effects include pigmentation changes and hypertrichosis (excess hair growth). In rare cases, treating psoriasis with corticosteroids—or their withdrawal—has been associated with the pustular form of the disease. Clobetasol Propionate is usually well tolerated, but application should be stopped immediately if signs of hypersensitivity appear, as exacerbation of symptoms may occur.

Pregnancy: Data on the use of Clobetasol Propionate cream in pregnant women are limited. Topical administration of corticosteroids to pregnant animals can cause abnormalities of foetal development, though the relevance of this finding to humans has not been established. Clobetasol Propionate should be used during pregnancy only if the expected benefit to the mother outweighs the potential risk to the foetus.

Lactation: It is not known whether Clobetasol Propionate is excreted in human breast milk. Since many drugs pass into breast milk, caution should be exercised when it is used by a nursing mother.

Long-term continuous topical therapy should be avoided wherever possible, particularly in infants and children, because adrenal suppression can occur readily even without occlusion. When used in childhood or on the face, courses should be limited to five days where possible, and occlusion should not be used.

The face is more prone than other body areas to atrophic changes after prolonged treatment with potent topical corticosteroids—an important consideration when treating conditions such as psoriasis, discoid lupus erythematosus, and severe eczema.

If applied to the eyelids, take care that the preparation does not enter the eye, as glaucoma or cataract may result.

Topical corticosteroids may be hazardous in psoriasis for several reasons, including rebound relapses on withdrawal, development of tolerance, risk of generalised pustular psoriasis, and local or systemic toxicity due to impaired skin barrier function. Careful patient supervision is essential when used for psoriasis.

Appropriate antimicrobial therapy should be used whenever inflammatory lesions become infected. Any spread of infection requires withdrawal of the topical corticosteroid and systemic antimicrobial treatment. Because the warm, moist conditions created by occlusive dressings encourage bacterial infection, the skin should always be cleansed before applying a fresh dressing.

Acute overdosage is very unlikely with topical use. However, chronic overuse or misuse may lead to features of hypercortisolism. In such cases, the topical corticosteroid should be gradually discontinued under medical supervision.

Store below 30°C, protected from light and moisture. Do not freeze. Keep out of the reach of children.

Infants and children under 12 years: Long-term continuous topical corticosteroid therapy should be avoided wherever possible, as adrenal suppression can occur. Children are more susceptible than adults to topical corticosteroids and are more likely to develop atrophic skin changes, so treatment should be kept as short as possible and closely monitored.